Effect of maternal immunization against pertussis in Medellin and the metropolitan area, Colombia, 2016–2017

Hincapié-Palacio, Doracelly; Hoyos, María Cristina; Ochoa, Jesús; Montoya, Nilton; García, Diego; Osorio, Elkin

doi:10.1016/j.vaccine.2018.05.020

Cited by 17 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary study objectives related to immunogenicity. Only two pertussis cases occurred among 1005 enrolled mothers and VE could not be estimated [96].…”

Section: Infants Up To 6 Months Of Age Two Studiesmentioning

confidence: 95%

“…Ten out of 11 articles reported on the vaccine effectiveness of maternal Tdap vaccination in preventing pertussis disease in infants [9,10,88-96] and 3 out of 11 provided information on the impact of the maternal immunization program on pertussis disease in infants [9,10,88] (Table 2 and Table 3). All of the included studies were observational; six were cohort studies, four were case-control studies, and one was a timeseries analysis that compared pertussis incidence between states with a high (>50%) and low (≤50%) Tdap vaccine coverage in Argentina [9,10,[88][89][90][91][92][93][94][95][96]. Case-control studies used surveillance and notification data to identify cases and three of the four studies matched controls for age and place of birth [89][90][91][92].…”

Section: Effectiveness Of Maternal Immunization and Impact On Infant mentioning

confidence: 99%

“…Case-control studies used surveillance and notification data to identify cases and three of the four studies matched controls for age and place of birth [89][90][91][92]. Three cohort studies used large healthcare claims databases or statewide surveillance data and two used the screening method to compare maternal Tdap vaccination coverage in pertussis cases identified through national surveillance, with average national coverage rates [9,10,[93][94][95][96]. One cohort study recruited mothers from clinics and followed them for 6 months after delivery [96].…”

Section: Effectiveness Of Maternal Immunization and Impact On Infant mentioning

confidence: 99%

“…Three cohort studies used large healthcare claims databases or statewide surveillance data and two used the screening method to compare maternal Tdap vaccination coverage in pertussis cases identified through national surveillance, with average national coverage rates [9,10,[93][94][95][96]. One cohort study recruited mothers from clinics and followed them for 6 months after delivery [96]. Studies of VE were conducted in Argentina, Australia, Brazil, Colombia, Spain, the UK, and the US between 2010 and 2016, and studies of impact were conducted in Argentina and the UK between 2010 and 2015.…”

Section: Effectiveness Of Maternal Immunization and Impact On Infant mentioning

confidence: 99%

“…A cohort study in Colombia by Hincapie-Palacio et al, followed infants born to vaccinated and non-vaccinated mothers from birth until 6 months of age [96]. The primary study objectives related to immunogenicity.…”

Section: Infants Up To 6 Months Of Age Two Studiesmentioning

confidence: 99%

See 4 more Smart Citations

A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis

Kandeil

Ende²,

Bunge³

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Infants too young to be fully immunized are the most vulnerable to severe pertussis disease. To close this susceptibility gap, passive infant immunization through vaccination of pregnant women against pertussis was first introduced in 2011 in the United States and has been extended since then to more than 40 countries. Areas covered: We conducted two systematic literature searches to describe the worldwide burden of pertussis disease in infants <6 months of age since 2005, and the effectiveness and impact of maternal pertussis vaccination in preventing infant pertussis since 2011. Expert opinion: Pertussis disease incidence rates in infants aged <2-3 months were substantial in all countries with available data, exceeding 1000 cases per 100,000 population during outbreaks. Virtually all pertussis deaths occurred in this age group. Data from Africa, Eastern Mediterranean, and Asia were limited, but suggest a similar or higher disease burden than in Europe or the Americas. Estimates of effectiveness of second/third trimester pertussis vaccination in preventing pertussis disease in <2-3 months old infants were consistently high (69%-93%) across the observational studies reviewed, conducted in various settings with different designs. Maternal vaccination programs appear to be achieving their goal of reducing the burden of disease in very young infants.

show abstract

“…The primary study objectives related to immunogenicity. Only two pertussis cases occurred among 1005 enrolled mothers and VE could not be estimated [96].…”

Section: Infants Up To 6 Months Of Age Two Studiesmentioning

confidence: 95%

Section: Effectiveness Of Maternal Immunization and Impact On Infant mentioning

confidence: 99%

Section: Effectiveness Of Maternal Immunization and Impact On Infant mentioning

confidence: 99%

Section: Effectiveness Of Maternal Immunization and Impact On Infant mentioning

confidence: 99%

Section: Infants Up To 6 Months Of Age Two Studiesmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis

Kandeil

Ende²,

Bunge³

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

The current state of pertussis vaccination in pregnancy around the world, with recommendations for improved care: Consensus statements from the Global Pertussis Initiative

Olson‐Chen,

Swamy,

Gonik

et al. 2024

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Bordetella pertussis, which causes a respiratory disease known as pertussis ("whooping cough") remains an important global challenge, with the incidence in pertussis cases increasing in recent years. Newborns and infants are at increased risk for severe morbidity and mortality from this bacterium. Vaccination in pregnancy has become an important strategy to both passively transfer immunity as well as prevent infection in pregnant persons, who are a major source of newborn infection, thus attempting to decrease the impact of this serious disease. It is considered safe for the pregnant person, the developing fetus, and the infant, and during the first 3 months of life it has been shown to be highly effective in preventing pertussis. There are a variety of strategies, recommendations, and adherence rates associated with pertussis vaccination in pregnancy around the world. We summarize the 2021 Global Pertussis Initiative Annual Meeting that reviewed the current global status of pertussis vaccination in pregnancy and remaining medical and scientific questions, with a focus on vaccination challenges and strategies for obstetric and gynecologic healthcare providers.

show abstract

Immunological and Clinical Benefits of Maternal Immunization Against Pertussis: A Systematic Review

2019

View full text Add to dashboard Cite

Infants are vulnerable to pertussis infection particularly before initiation of pertussis vaccination. Maternal pertussis vaccination during pregnancy has been introduced in a number of countries in order to confer on young infants indirect protection from the disease through transplacental transfer of maternal antibodies. We reviewed the evidence on the immunogenicity and efficacy of maternal pertussis vaccination during pregnancy. A systematic search of PubMed/MEDLINE, EMBASE, Scopus, Cochrane Database of Systematic Reviews, ProQuest, and Science Direct was undertaken to identify studies published between January 1995 and December 2018. This review was not specific to any particular pertussis vaccine but included applicable data on available pertussis vaccines administered to pregnant women. The search identified 40 publications for inclusion in this review. Vaccination during pregnancy elicited robust maternal immune responses against all vaccine antigens and resulted in high placental transfer of pertussis antibodies to the infant that persisted well beyond delivery. Vaccination during the second or early third trimesters was considered ideal for antibody quantity and functionality. Although blunting of immune responses to some antigens in the primary immunization series was documented in neonates born to women vaccinated during pregnancy, there was no apparent adverse effect on vaccine efficacy. Multiple studies conducted in diverse settings have confirmed the effectiveness of maternal pertussis vaccination during pregnancy in preventing pertussis in infants prior to receipt of their first primary vaccine dose and beyond. These findings collectively underscore the value of maternal pertussis vaccination during pregnancy in protecting vulnerable infants too young to be vaccinated.

show abstract

Effect of maternal immunization against pertussis in Medellin and the metropolitan area, Colombia, 2016–2017

Cited by 17 publications

References 22 publications

A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis

A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis

The current state of pertussis vaccination in pregnancy around the world, with recommendations for improved care: Consensus statements from the Global Pertussis Initiative

Immunological and Clinical Benefits of Maternal Immunization Against Pertussis: A Systematic Review

Contact Info

Product

Resources

About